Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Tencent Music Entertainment Group - ADR — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Tencent Music Entertainment Group - ADR trades at $8.83 (market cap $14.27B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 3.2× ACADIA Pharmaceuticals Inc.'s market cap, and Tencent Music Entertainment Group - ADR pays a 2.78% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TME | |
|---|---|---|
Market Cap | $4.49B | $14.27B |
Sector | Health | Media |
52-Week High | $28.06 | $26.36 |
52-Week Low | $20.06 | $8.16 |
Enterprise Value | $3.69B | $11.05B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TME trades at $8.62, showing slight daily weakness. The stock presents a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported strong revenue growth to $32.90B in 2025 with a robust net income margin of 26.48%, though recent quarterly earnings have missed expectations. Analyst sentiment is divided with a consensus price target of $14.00, representing significant upside potential from current levels.
The investment case for TME hinges on its solid profitability and reasonable valuation multiples, but faces headwinds from competitive pressures and recent earnings misses. Key risks include intensifying competition in China's music streaming market and potential regulatory scrutiny. The consensus view suggests moderate bullishness with the stock trading below analyst targets, though execution on growth initiatives remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
